Augustine Therapeutics

Augustine Therapeutics

Discovering and developing innovative medicines for the treatment of neuromuscular and neurodegeneratives diseases.

HQ location
Leuven, Belgium
Launch date
Employees
Enterprise value
$342—513m
Company register number
  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round
investor investor investor investor investor

€0.0

round
investor investor investor investor investor investor investor investor

€0.0

round
*

€77.7m

Series A
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2020202120222023
Revenues0000000000000000
EBITDA0000000000000000
Profit0000000000000000
EV0000000000000000
EV / revenue00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x
R&D budget0000000000000000

Source: Company filings or news article

More about Augustine Therapeutics
Made with AI
Edit

Augustine Therapeutics is a Belgium-based biotech startup that focuses on developing innovative therapies for complex neurological disorders, particularly those associated with axonal dysfunction. The company's primary target is Charcot-Marie-Tooth (CMT), a rare hereditary disorder, and Chemotherapy-Induced Peripheral Neuropathy (CIPN), a condition caused by chemotherapy. Augustine Therapeutics aims to advance the understanding of axonal protection, regeneration, and remyelination, and translate this knowledge into effective treatments for patients with unmet medical needs.

The company's business model revolves around the development of novel therapeutics that can achieve reinnervation, with the goal of slowing down or even reversing the disease. This could provide significant relief for patients affected by axonopathies, a group of diseases characterized by the degeneration of nerve axons. Augustine Therapeutics' assets also have potential applications in other complex neurological disorders.

Currently, the company has three programs in development. The first program is advancing into preclinical development and targets peripherally restricted and selective HDAC6i for CMT and CIPN. The second program, focusing on brain penetrant and selective HDAC6i, is advancing into lead optimization. The third program, targeting subtype-selective GABABR1A activators for CMT1, is at the discovery stage.

Founded in 2019, Augustine Therapeutics is rooted in the groundbreaking research of the VIB laboratory of Ludo Van Den Bosch and the collaboration between the VIB labs of Joris de Wit and Bart De Strooper. The company operates in the biotech market, serving patients suffering from severe peripheral nerve disorders.

Keywords: Biotech, Neurological Disorders, Axonal Dysfunction, Charcot-Marie-Tooth (CMT), Chemotherapy-Induced Peripheral Neuropathy (CIPN), Axonal Protection, Reinnervation, Therapeutics Development, Peripheral Nerve Disorders, HDAC6i.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo